Skip to Content
COVID-19 Resources
Contact DCTD
Show menu
Search this site
Last Updated: 05/04/2021

2021 American Association for Cancer Research (AACR) Annual Meeting

Schedule of DCTD Presentations

DCTD-supported research will be presented at the virtual AACR Annual Meeting External Link April 10-15, 2021 and May 17-21, 2021.

Oral Presentations

Date/Time Title ID
April 11
2:50 PM - 3:00 PM
Molecular dissection of chemotherapy response in triple negative breast cancer (TNBC) using microscaled proteogenomics External Link

DCTD Authors: Henry Rodriguez, Ana Robles
18
April 12
1:35 PM - 1:45 PM
Integrative surfaceome profiling identifies immunotherapeutic targets in osteosarcomas (OS); Preclinical testing of BT1769, an MT1-MMP-targeted Bicycle® Toxin Conjugate, in OS by the Pediatric Preclinical Testing Consortium (PPTC) External Link

DCTD Author: Malcolm Smith
LB008
May 17
9:45 AM - 10:45 AM
NCI Consortia Initiative and Resource: Proteomics and Proteogeomics

DCTD Chair and Speakers: Ana I. Robles (C), Henry Rodriguez, Erika Kim, Justin Kirby, Ana I. Robles, Mehdi Mesri
 
May 21
9:45 AM - 10:45 AM
The Cancer Imaging Archive (TCIA)

DCTD Speaker: John Freyman
 

Poster Presentations

Title and DCTD First Author ID
Saturday, April 10 — 8:30 AM — 11:59 PM
LASSO-based protein signatures for survival prediction in human cancer cohorts External Link

Mariam Konate, BRP
160
SCLC-CellMiner: An Extensive Cell Line Genomic and Pharmacology Resource identifies a subgroup of small cell lung cancers sensitive to targeted therapies and immunotherapies External Link 203
Sarcoma-CellMiner: An extensive resource for patient-derived sarcoma cell line epigenetics, genomics and pharmacology External Link 212
A standard operating procedure for the curation of gene fusions External Link 449
Early antibiotic exposure delays disease progression following immune checkpoint inhibitor therapy for hepatocellular carcinoma: Evidence from an observational study External Link 485
Germline cancer predisposition results from the National Cancer Institute — Children’s Oncology Group (NCI-COG) Pediatric MATCH Trial External Link 631
A phase I trial of Triapine and Lutetium Lu 177 Dotatate in combination for well-differentiated somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) External Link 674
Phase II trial of the Wee1 inhibitor adavosertib in advanced refractory solid tumors with CCNE1 amplification External Link 974
Combination screening of KRASG12C specific inhibitors with other targeted therapies in patient-derived multicellular tumor spheroids External Link 1028
Combination screening of DNA damaging agents temozolomide and trabectedin with inhibitors of DNA repair using a complex spheroid model with a panel of patient-derived and established tumor cell lines External Link 1072
Fostering engagement in biobanking and research through the NCI Cancer Moonshot℠ Biobank Participant and Provider Engagement Website External Link

Esmeralda Casas-Silva, CDP
2632
Comparison of PDMR cell line complex spheroid response and PDX response to trametinib External Link

Beverly Teicher, DTP
2644
Imaging characterization of NCI patient derived model repository (PDMR) xenografts External Link

Paula Jacobs, OD
3007
A systematic review of the tumor growth metrics of patient-derived xenograft (PDX) models in the literature and in the NCI PDXNet centers External Link 3009
Single agent response comparisons in a large-scale, preclinical trial of rare cancer PDXs by the National Cancer Institute’s patient-derived models repository External Link

Yvonne Evrard, FNLCR
3010
Patient-derived models of rare cancers in the National Cancer Institute’s patient-derived models repository External Link

Cindy Timme, FNLCR
3012
Applications of immunohistochemistry in characterization of patient derived xenograft models External Link

Lindsay Dutko, FNLCR
3015
Advancing PDX research through model, data, and bioinformatics with the PDXNet Portal External Link 3017
Integrative genomics reveals IncRNAs associated with pediatric cancer External Link 3028
Evaluation of ROR1-targeted antibody-drug conjugates against ROR1-expressing pediatric preclinical models — a report from the pediatric preclinical testing consortium (PPTC) External Link 3038
Pediatric preclinical testing consortium evaluation of the dual SYK/FLT3 inhibitor TAK-659 in xenograft models of pediatric acute lymphoblastic leukemia External Link 3039
Pan-cancer stemness defined by CPTAC proteogenomics guides personalized therapies External Link 3113
Study of tumor heterogeneity and subclonality in primary pancreatic and metastatic sites from rapid autopsy patients in PDMR External Link

Li Chen, FNLCR
3139
Phase I trial of the triplet berzosertib (M6620, VX-970), veliparib and cisplatin (BVP) in patients with advanced solid tumors External Link CT115
Phase I trial of the combination of bortezomib and clofarabine in adults with refractory solid tumors, lymphomas, or myelodysplastic syndromes External Link CT138
The differentiated CD47 monoclonal antibody AO-176 exhibits significant in vivo activity against xenograft models of pediatric acute lymphoblastic leukemia (ALL) External Link LB171
Evaluation of the pan-class I phosphoinositide 3-kinase (PI3K) inhibitor Copanlisib in the Pediatric Preclinical Testing Consortium osteosarcoma in vivo models External Link LB252

Meet-the-Expert Presentations (Video Information)

Date/Time Topic Presenter
Thursday, May 6
1:00-1:30 PM
NCI-Cancer Diagnosis Program Initiatives, Funding Opportunities and Research Resources for Investigators Aniruddha Ganguly, CDP
Monday, May 10
1:00-1:30 PM
The NCI National Clinical Laboratory Network Tracy Lively, CDP
Tuesday, May 11
1:00-1:30 PM
NCI National Clinical Trials Network (NCTN) and Cooperative Human Tissue Network (CHTN) Biospecimens Available for the Cancer Research Community Irina Lubensky and Rodrigo Chuaqui, CDP
Wednesday, May 12
1:00-1:30 PM
Funding Opportunities at Other ICs for Cancer Research Sundar Venkatachalam, DTP